New combined therapy helps extend lives of men with prostate cancer

Practice-changing research shows that a combination of androgen deprivation therapy -- a commonly used hormone injection -- plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients' prostate cancer at bay for five years.